tbuckley/cabot-search huggingface dataset:
CD20 Antigen Density at Time of Presentation Is An Independent Predictor of Outcome in B-Cell Lymphoproliferative Disorders
Authors: Sapna Khubchandani, Terry Mashtare, Mohammad Muhsin Chisti, Gregory Wilding, Scott Olejniczak, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2008)
FRI0416 Evaluating The Impact of A Local Inflammatory Back Pain Awareness Campaign in The United Kingdom:
Authors: G. Tracey, J. McCaulder-Ojeda, R. Sengupta
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The average delay to diagnosis in the UK is 8.5 years, even though the majority of patients consult their GP within one year of symptom onset. The lack of awareness and recognition of IBP (Inflammatory Back Pain) is one of the main reasons for the unacceptable delay in diagnosis<sup>1</sup>. A public awareness campaign to raise awareness of IBP was held in Bath on 13th September 2014 <h3>Objectives</h3> The aim of the study was to assess referral rates pre and post campaign - number of referrals for IBP, number of newly diagnosed Axial Spondyloarthritis (AxSpa)/ Ankylosing Spondylitis (AS) and mechanical back pain patients who were referred with reference to IBP and for new AxSpa/AS patients - age, length to diagnosis from symptom onset, sex, HLA B27 status and CRP were also assessed. <h3>Methods</h3> Referrals to the Royal National Hospital for Rheumatic Diseases (RNHRD), Bath Pre Campaign from January-March 2014 and Post Campaign in Months October-December 2014 were evaluated. Referral letters were reviewed and categorised as either likely inflammatory referrals or likely non-inflammatory referrals. A referral was considered as inflammatory if it contained key words such as Sacroiliitis, HLA B27 status, mention of Family history of Ankylosing spondylitis/Axial spondyloarthritis, spondyloarthropathy or inflammatory back pain/arthropathy Based on history and investigations, patients were classified using the ASAS Axial SpA classification criteria as either nr-AxSpa orAS, or if they didn9t meet the criteria “Mechanical Back pain”. It was assessed whether this was a new or an old diagnosis. <h3>Results</h3> There were 91 back pain referrals pre campaign and 96 post campaign. Pre campaign, 40 patients with AxSpa were referred. 8/40 were diagnosed as new AS (20%) and 16 had known AS. 10/40 (25%) were diagnosed as new nrAxSpa. 6 had known nrAxSpA. Of the 18 new AxSpa cohort 14 had “inflammatory” referrals from the referrer. ie. 77% accurate referrals.51 cases of mechanical back pain were diagnosed; 19 of the referrals contained “inflammatory” key words Post campaign,38 patients with AxSpA were referred. 3/38 were diagnosed with new AS. 11/38 were diagnosed with new nrAxSpa. 12/14 of new AxSpa patients had “inflammatory” referrals.ie 85% accuracy. 58 cases of mechanical back pain were diagnosed; 21 of the referrals had “inflammatory” key words. <h3>Conclusions</h3> In a local setting, the campaign did not significantly increase the number of new back pain referrals to rheumatology. Reassuringly, we found that the index of suspicion from referrers for AxSpA to be high in both cohorts. <h3>References</h3> Hamilton L, Gilbert A, Skerrett J, Dickinson S, Gaffney K. Services for people with ankylosing spondylitis in the UK–a survey of rheumatologists and patients. Rheumatology (Oxford, England). 2011 Nov;50(11):1991–8. <h3>Disclosure of Interest</h3> None declared
CONGENITAL PYLORIC STENOSIS
Authors: C. M. Page
Journal: BMJ (1931)

MDCAL JOURNAL' to a direct injury, would have been very much worse.As this haemorrhage is absorbed so will the function of the pituitary increase, and the patient already shows signs of improvement in that less pituitary extract is req-uired to control the thirst and polyuria.The necessity for early recognition of diabetes insipidus cannot be too strongly emphasized, as the polyuria in time has a deleterious effect upon the kidneys and bladder.Pituitary extract hypodermically is without doubt the treatment of choice, but it must be remembered that it is not a cure.The treatment must be maintained and the co-operation of the patient sought.In conclusion, I desire to express my indebtedness to Mr. Blair for the facilities he has afforded me in observing this case.
ATIM-23. PHASE 1 DOSE ESCALATION STUDY OF CONTROLLED INTRATUMORAL VIRAL DELIVERY OF Ad-RTS-hIL-12 + ORAL VELEDIMEX IN SUBJECTS WITH RECURRENT OR PROGRESSIVE HIGH-GRADE GLIOMA
Authors: Francois Lebel
Journal: Neuro-Oncology (2016)

Ad-RTS-hIL-12 is a novel gene therapy candidate expressing IL-12 under the control of an orally administered activator ligand, veledimex, through the proprietary RheoSwitch Therapeutic System® (RTS®) gene switch. For Glioblastoma patients who experienced multiple recurrences the prognosis is particularly poor, with a median overall survival (OS) of 6-7 months, while in patients who failed temozolomide and bevacizumab, or equivalent salvage chemotherapy, it is approximately 3-5 months. In this multicenter Phase I dose-escalation trial, subjects with recurrent or progressive high-grade glioma undergoing resection were intratumoraly injected once with Ad-RTS-hIL-12 2x1011vp with 15 daily oral doses of veledimex (Arm 1). Subjects not scheduled for tumor resection will receive Ad-RTS-hIL-12 by stereotactic injection followed by 14 daily oral doses of veledimex (Arm 2). The primary endpoint is safety and tolerability with secondary endpoints including OS. Current results in 13 subjects in Arm 1 ((20mg; n=7; 40mg n=6), (8 males and 5 females, ages 32-58)) demonstrated that veledimex crossed the blood-brain-barrier with ~32% and 46% of plasma level detected in the tumor. Veledimex at 20 and 40mg demonstrated dose-related increases in tumor concentration (5 and 25pg/g) concomitant with increases in serum IL-12 (21 and 63pg/ml) and downstream IFNg (27 and 70pg/ml), respectively. Blood FACS analysis showed increases in CD8 T-cells, and ratio of CD8/CD4 and CD8/FoxP3 vs. baseline. Adherence to assigned dosing was higher at 20mg than 40mg (86% Cohort 1; 51% Cohort 2). Observed toxicities were expected, rapidly reversible following discontinuation of veledimex, but seen at higher frequency at 40mg. Neurotoxicities were minimal and manageable. We previously reported 6-month survival at 100%; 12-month survival will be reported. We are accruing additional patients, including in the stereotactic arm. Intracranial administration of Ad-RTS-hIL-12 +veledimex is well tolerated, suggesting likely survival benefit vs. historical control providing a strong rationale for a pivotal trial.
Inferior Outcome in Patients with Acute Promyelocytic Leukemia and High Expression of the Ets Related Gene: Role in Leukemogenesis and Potential Implications for Future Therapeutic Approaches?,
Authors: Anna Hecht, Florian Nolte, Daniel Nowak, Verena Nowak, Benjamin Hanfstein, Andreas Faldum, Thomas Buchner, Karsten Spiekermann, Cristina Sauerland, Eva Lengfelder, Wolf-Karsten Hofmann
Journal: Blood (2011)
Percutaneous Coronary Intervention Without On-site Cardiac Surgery
Authors: H. Vernon Anderson
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Voluntary euthanasia deaths in Quebec outstrip predictions by three to one
Authors: Owen Dyer
Journal: BMJ (2016)

The number of assisted deaths in Quebec since medical assistance in dying was legalised was three times higher than expected, according to the province’s health minister.

“I mentioned many times that I was expecting about 100,” Gaetan Barrette told a news conference. “It’s almost three times that. Actually, in a one year period it will be over 300.”

Georges L’Esperance, president of the Quebec Association for the Right to Die with Dignity, said in January …
PWE-076 Specialist Centre Patient Volume Does Not Impact on Endoscopic Outcomes for Treatment of Barrett’s Dysplasia. Results from The UK Registry
Authors: G Lipman, A Gupta, M Banks, R Sweis, JM Dunn, D Morris, H Smart, P Bhandari, RP Willert, G Fullarton, AJ Morris, M Di Pietro, P Mundre, C Gordon, I Penman, H Barr, P Patel, P Boger, N Kapoor, BS Mahon, J Hoare, R Narayanasamy, D O’Toole, Y Ang, A Veitch, D Nylander, A Dhar, K Ragunath, A Leahy, M Fullard, R Haidry, LB Lovat
Journal: Gut (2016)

<h3>Introduction</h3> Endoscopic mucosal resection (EMR) followed by Radiofrequency ablation (RFA) is first line treatment for mucosal Barrett’s oesophagus (BE) related neoplasia. The UK Registry collects data from patients at 28 sites undergoing RFA/EMR. We examine differences in outcomes between sites by patient volume. <h3>Methods</h3> All visible lesions were entirely removed by EMR. Patients then underwent RFA every 3 months until all visible BE was ablated. Biopsies were taken at 12 months to assess treatment success with repeat biopsies every 6–12 months thereafter. Centres were grouped by total numbers treated; low &lt;50, medium 50–100 &amp; high &gt;100 patients. Only outcomes of those who had completed treatment were analysed. <h3>Results</h3> 675 patients completed treatment at 24 centres (median follow up 26 months), 414 at high volume (n = 5), 143 at medium volume (n = 4) &amp; 118 at low volume centres (n = 15). There was no difference in entry criteria or demographics between groups. CR-D &amp; CR-IM at 12 months are no different between the groups (CR-D 86–90%, CR-IM 74–81%). IM recurrence is significantly lower in high volume centres (16.1% vs 20.3% and 19.2%, Log Rank p &lt; 0.001) but dysplasia recurrence is no different (Log Rank p = 0.12). Rescue EMR was performed less frequently in medium volume centres (0% vs high 5.3% and low volume 10%, p = 001). <h3>Conclusion</h3> Endotherapy for Barrett’s dysplasia is highly effective whatever the centre volume. The rescue EMR rate in medium volume centres is unexplained. Despite lower IM recurrence in high volume centres, dysplasia recurrence rates are not significantly different. Caseload volume of a centre in the UK Registry does not appear to affect outcome. <h3>Disclosure of Interest</h3> None Declared
Somatic Gene Mutations Serve As Molecular Biomarkers Predictive for Response to Immunosuppressive Therapy (IST) in Myelodysplastic Syndromes (MDS)
Authors: Rami S. Komrokji, Mintallah Haider, Najla H. Al Ali, Jeffrey E Lancet, Qing Zhang, Pearlie K Epling-Burnette, Alan F. List, Eric Padron
Journal: Blood (2015)
Low Predictive Value of Functional Imaging with 18FDG-PET or Gallium Scanning in Relapsed or Refractory Hodgkin Lymphoma Prior to Autologous Stem Cell Transplantation.
Authors: Stefan Peinert, Rosemary Hoyt, Jeff Szer, Andrew Roberts, Andrew Grigg, H. Miles Prince, Luigi Rigacci, John F. Seymour, David S. Ritchie
Journal: Blood (2007)
Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.
Authors: Irene M. Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, Ashraf Z. Badros, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul Richardson, M.D., Steven Treon, Edie Weller, Jeffrey Matous
Journal: Blood (2009)
Dynamic Telomere Shortening and Chromosomal Instability in Irradiated CD34+ Cells Transduced with TP53 Hotspot Mutations R175H, R248W and R249S
Authors: Azam Salari, Kathrin Thomay, Andrea Schienke, Maike Hagedorn, Juliane Ebersold, Andreas Krueger, Axel Schambach, Brigitte Schlegelberger, Gudrun Göhring
Journal: Blood (2015)
SAT0034 Nicotine Is A Potent Driver of Netosis and Accelerates Collagen-Induced Arthritis
Authors: J. Lee, A. Luria, C. Rhodes, H. Raghu, O. Sharpe, W. Robinson, J. Sokolove
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Cigarette smoking is a major risk factor for rheumatoid arthritis (RA). The contribution of nicotine, the most ubiquitous and addictive component in the traditional as well as electronic cigarettes (e-cigarettes), to the development of RA remains unclear. Recent evidences implicate aberrant Neutrophil Extracellular Trap (NET) formation in the pathogenesis of RA. <h3>Objectives</h3> This study was undertaken to investigate the effect of nicotine on NETosis and its ability to potentiate arthritis in a murine model of RA. <h3>Methods</h3> Human neutrophils were incubated with nicotine in the presence of DNA-binding dye (Sytox) to quantify NETosis. In parallel, levels of NET-associated myeloperoxidase (MPO)/DNA complexes were measured using a novel NET-specific ELISA. Immunofluorescent staining was used to perform microscopic kinetic analysis of NETosis and to assess the presence of nicotinic acetylcholine receptors (nAChRs) in these neutrophils. NETosis were measured after stimulating neutrophils with GTS-21 (α7-specific nAChR agonist) or mecamylamine (an AChR antagonist). Finally, the effect of systemic nicotine exposure on arthritis development and progression was investigated using subcutaneous osmotic nicotine pumps in the collagen-induced arthritis (CIA) mouse model. <h3>Results</h3> Neutrophils derived from current smokers displayed significantly higher level of spontaneous- and PMA-induced NETosis as measured by Sytox assay and by NET-specific ELISA. In line with this, nicotine enhanced NETosis in a dose-dependent manner in vitro. Furthermore, incubation with APCA-immune complexs or TNF-α facilitated priming of neutrophils to undergo nicotine-induced NETosis. Immunofluorescent staining revealed that nicotine induced robust formation of NET-like structure in these neutrophils. Cell surface staining with an α7-specific agonist (α-bungarotoxin) and anti-α7-specfic antibody demonstrated co-localization on the plasma membrane. Nicotine-induced NETosis was reproduced when stimulated with GTS-21 and was abrogated when neutrophils were pretreated with mecamylamine. A significantly increased arthritis score as measured by paw swelling and thickness was observed in CIA mice treated with nicotine compared with vehicle treated controls. <h3>Conclusions</h3> Our data indicate that nicotine is a potent inducer of NETosis and may play an important role in the initiation and propagation of RA. Furthermore, our study provides molecular evidence for public awareness and clinical guidance against the use of nicotine-containing products including e-cigarettes in patients with RA. <h3>Disclosure of Interest</h3> None declared
Cytogenetic and FISH Study of 92 Patients with Splenic Marginal Zone B-Cell Lymphoma (SMZBCL).
Authors: Marta Salido, Francesc Sole, Blanca Espinet, Eva Gimeno, Lourdes Florensa, Isabel Granada, Laura Astier, Alicia Domingo, Manuela Mollejo, Jose A. Martinez-Climent, Juan L. Garcia, Isana Benet, Jesus M. Hernandez, Pedro Martinez, Miguel A. Piris, Encarna Perez-Vila, Soledad Woessner, Elias Campo, Sergio Serrano
Journal: Blood (2004)
Adding Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy to Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) in Patients (pts) with Advanced Hematological Malignancies.
Authors: Joseph Rosenthal, Jeffrey Y. Wong, George Somlo, David Snyder, Margaret O’Donnell, Anthony Stein, Ayurporn Nademanee, Maria Delioukina, Leslie Popplewell, Pablo Parker, Ricardo Spielberger, Firoozeh Sahebi, Chatchada Karanes, Debbie Hitt, Hossameldin Naeem, Andrew Dagis, Stephen Forman
Journal: Blood (2008)
Suppression of Let-7b MicroRNA and Enhanced Its Target genes in Infant Acute Lymphoblastic Leukemia with MLL Gene Rearrangements.
Authors: Masanori Nishi, Yujirou Sadakane, Mariko Eguchi, Minenori Eguchi-Ishimae, Hisamichi Tauchi, Sanae Kawakami, Daisuke Tomizawa, Shuki Mizutani, Kanji Sugita, Eiichi Ishii
Journal: Blood (2009)
PWE-068 Higher Diagnostic Yield, Younger Age and Improved Performance Status at Diagnosis Associated with The National Oesophago-Gastric (OG) Awareness Campaign (2015) – A District General Hospital Perspective
Authors: CA Coombs, L Pope, M O’Donnell, DS Pearl
Journal: Gut (2016)

<h3>Introduction</h3> A retrospective study evaluating the impact of the English national oesophageal and gastric cancer awareness campaign (26/01/2015-22/02/2015) on a large district general hospital (DGH). The campaign involved radio and television broadcasts advising medical assessment for dysphagia or persistent dyspepsia. <h3>Methods</h3> Data from all two week wait (2 ww) OG referrals triaged to gastroscopy (OGD) from January to July in 2014 and 2015, was audited retrospectively. The Somerset Cancer Register (SCR) database was used for data collection. Age and World Health Organisation (WHO) performance status, recorded at point of referral, was retrieved from the SCR. Number of referrals, cancer diagnoses, age, WHO performance status and treatment intent were compared between an identical 6 month period in 2014 and 2015. Formal statistical analysis was not carried out. <h3>Results</h3> There was a 26% increase in 2 ww referrals from 2014 to 2015 (530 to 667) and 4% in non 2 ww referrals (477 to 496). The number and percentage (%yield) of OG cancer diagnoses from 2 ww referrals was 27 (5.0%) in 2014 compared to 32 (4.8%) in 2015. The number and percentage (%yield) of OG cancer diagnoses from routes other than 2 ww OG referral was 17 (3.6%) in 2014 compared to 26 (5.2%) in 2015. The mean and median age at diagnosis expressed in years was 77 and 79 (2014) compared with 69 and 75 (2015). Of OG cancer diagnoses, the treatment intent was considered potentially curative in 33% (2014) compared with 34% (2015). Percentage of patients recorded as WHO performance status 0 and 1 combined was 74% (2014) compared to 91% (2015). One year mortality data is not yet available due to early reporting. <h3>Conclusion</h3> The 26% increase in 2 ww OG referrals is likely to be heavily influenced by the national OG awareness campaign, on the background of an 11% per annum increase in demand for diagnostic endoscopy services. Interestingly the percentage of cancer findings at OGD remained around 5% indicating that the increased diagnostic throughput has translated to OG cancer diagnoses. The mean and median age at diagnosis was 8 and 4 years lower respectively; this may indicate earlier patient directed self-referral to primary care with OG symptoms, suggesting that the campaign has reached its target audience. Unfortunately, there was not been an obvious increase in potentially curative OG cancer diagnoses; however, the younger group and better performance status may support more intense oncological therapy, leading to improved outcomes. <h3>Disclosure of Interest</h3> None Declared
Description of 13 Infants Born During October 2015–January 2016 With Congenital Zika Virus Infection Without Microcephaly at Birth — Brazil
Authors: Vanessa van der Linden, André Pessoa, William Dobyns, A. James Barkovich, Hélio van der Linden Júnior, Epitacio Leite Rolim Filho, Erlane Marques Ribeiro, Mariana de Carvalho Leal, Pablo Picasso de Araújo Coimbra, Maria de Fátima Viana Vasco Aragão, Islane Verçosa, Camila Ventura, Regina Coeli Ramos, Danielle Di Cavalcanti Sousa Cruz, Marli Tenório Cordeiro, Vivian Maria Ribeiro Mota, Mary Dott, Christina Hillard, Cynthia A. Moore
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Craniofacial disproportion at birth
In Vivo Imaging and Tracking of Defined, Repopulating Human Stem Cell Subsets Using Fluorescence Conjugated Nanoparticles in a Clinically Applicable Ex Vivo Protocol.
Authors: Jesper Bonde, Dustin J. Maxwell, David A. Hess, Ryan Lahey, Michael H. Creer, David Piwnica-Worms, Jan A. Nolta
Journal: Blood (2005)
Clonal Hematopoiesis in Philadelphia Chromosome-Negative Bone Marrow Cells of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors
Authors: Ron Paquette, John Nicoll, Meenal Chalukya, Lukasz P Gondek, Monika Jasek, Charles Sawyers, Neil Shah, Jaroslaw Maciejewski
Journal: Blood (2008)
Prevalence of comorbidity and associated risk factors in adults with atopic dermatitis
Authors: A. Egeberg, Y. M. F. Andersen, G. H. Gislason, L. Skov, J. P. Thyssen
Journal: Allergy (2016)

Atopic dermatitis (AD) is a common chronic skin disorder, which may persist into adulthood; however, the prevalence of comorbidities in patients with AD is not well characterized. AD is considered a systemic disorder like psoriasis, which has raised a need for data on the comorbidity profile of patients with AD, to assess the potential risks, benefits, and complications in management of patients with AD. We described the occurrence of medical and psychiatric comorbidities and associated risk factors in adults with AD compared with psoriasis and the general population.All Danish individuals aged ≥18 years with a hospital (inpatient or ambulatory) diagnosis of AD or psoriasis during the study period (January 1, 1995-December 31, 2012) were linked in administrative registers.Overall, prevalence of smoking and alcohol abuse was higher among patients with AD than the general population, but lower than psoriasis patients. Similarly, patients with AD had more risk factors and higher prevalence of comorbidity than the general population, but lower prevalence and reduced risk compared to psoriasis patients, except for use of anxiolytics, which was higher in severe AD. Prevalence of diabetes was lower in AD than psoriasis patients as well as general population controls.Despite an increased risk of various medical and psychiatric comorbidities compared to general population controls, adult patients with AD had markedly lower prevalence of cardiovascular disease than psoriasis patients. However, prevalence of psychiatric comorbidity and tobacco smoking was alarmingly high in severe patients with AD, which might be target for intervention in patient management.
SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM).
Authors: Sarah Waheed, Yazan Alsayed, Bijay Nair, Jackie Szymonifka, John D Shaughnessy, Frits van Rhee, Elias Anaissie, Bart Barlogie
Journal: Blood (2009)
Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma
Authors: Adrienne Greenough, Andrea Moffitt, Dereje Jima, Jane Healy, Amee Patel, Kristy L. Richards, Yuri D. Fedoriw, Cherie Dunphy, William W. L. Choi, Gopesh Srivastava, Magdalena Czader, Karen P. Mann, Christopher R. Flowers, Leon Bernal-Mizrachi, Kikkeri Naresh, Amy Chadburn, Leo I. Gordon, Andrew M. Evens, Javed Gill, Angela M. B. Collie, Eric D. Hsi, Cassandra L Love, Sandeep S. Dave
Journal: Blood (2014)
Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma
Authors: Brian A Walker, Christopher P Wardell, Alexander Murison, Eileen M Boyle, Lorenzo Melchor, Charlotte Pawlyn, Martin F Kaiser, Dil Begum, Nasrin Dahir, Paula Proszek, David C Johnson, Ya-Wei Qiang, John Jones, David A Cairns, Walter Gregory, Roger G Owen, Gordon Cook, Mark T Drayson, Graham Jackson, Faith E Davies, Gareth J. Morgan
Journal: Blood (2014)